Cells for Cells ('C4C'), a clinical-stage biotech pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the groundbreaking Clinical Data from the First-ever...
Read More
Recent Posts
- ISCT highlights observations from major Chilean advanced therapy developer group on Latin American regulation for Regenerative Medicine products in its recent Telegraft issue
- Chile’s Ministry of Science recognizes Cells for Cells as university spin-off success case in white paper
- Cells for Cells treats the first-ever patient with an exosome-produced therapy for osteoarthritis
- Cells for Cells presented groundbreaking results of three extracellular vesicles products at ISCT and ISEV annual meetings
- Cells for Cells featured in Startups Latam’s 2022 report